Schistosomiasis afflicts over 200 million people around the globe and is the deadliest disease among the seven most prevalent NTDs, killing an estimated 280,000 people annually. Thanks to private donations from Mr. Morton Hyman, Dr. Gary Michelson, Texas Children’s Hospital and the Blavatnik Family Foundation, the Schistosomiasis Vaccine Initiative (SVI) utilizes and leverages the Sabin Vaccine Institute PDP’s existing programmatic and technical infrastructure to produce and evaluate a schistosomiasis vaccine.
The suffering caused by hookworm is not well known in the developed world but in many countries it is all too prevalent. More than 700 million people are infected with hookworm. The largest number of cases occur in impoverished areas of Sub-Saharan Africa, Southeast Asia, China and Latin America. Globally, approximately 3.2 billion people are at risk for hookworm infection.
Hookworm is an intestinal parasite most commonly found in tropical and sub-tropical climates of Africa, Asia and Latin America. Hookworm, one of three members of a family of parasites known as the soil-transmitted helminths (STHs), are half-inch long worms that attach themselves to the intestinal wall and feed on human blood. Left untreated, hookworm causes severe intestinal blood loss leading to iron-deficiency anemia and protein malnutrition, particularly in pregnant women and children.
The development of a successful vaccine is a significant undertaking that takes years to achieve. The Sabin Vaccine Institute Product Development Partnership (PDP) is internationally recognized for its development of safe, effective vaccines against tropical infections including human hookworm, schistosomiasis, Chagas disease, leishmaniasis and SARS. Sabin PDP esteemed partners include:
With over a decade of experience, Sabin PDP has produced a well-rounded model that serves as a blueprint for the development of safe and effective vaccines against vaccine preventable and neglected tropical diseases. Existing capabilities include:
Product Development: Established the infrastructure to engage in antigen discovery, rapid development of scalable manufacturing processes (process development), quality control, preclinical and clinical immunology and stability testing.
The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today announced a new co
2011 Annual Report
September 11, 2012
On behalf of the trustees, management and staff of the Sabin Vaccine Institute, we are pleased to share our most significant accomplishments from the past year in our 2011 annual report.
The Sabin PDP has initiated development for a new therapeutic vaccine for Chagas disease that will be undertaken with partners in Mexico, where between two and six million people are infected with this leading cause of poverty in Latin America. Current efforts focus on the development of two vaccine candidate antigens that will ultimately comprise the first therapeutic vaccine for Chagas disease.